Heidelberg, Germany and Shanghai, China – May 8, 2025 – Full-Life Technologies ("Full-Life", the "Company"), a fully integrated clinical-stage global radiotherapeutics company, today announced the appointment of Debora Barton, MD, as Chief Medical Officer. 

With over 18 years of progressive experience spanning both established pharmaceutical companies and innovative biotech companies, Dr. Barton has consistently driven oncology clinical development programs to success. Immediately prior to joining Full-Life, she served as Chief Medical Officer at TScan Therapeutics (NASDAQ: TCRX) and Carisma Therapeutics (NASDAQ: CARM), where she secured multiple IND clearance for novel therapeutic candidates and designed and implemented strategic clinical development plans.

Dr. Barton stands as a preeminent expert in radiopharmaceutical clinical development. As Vice President and Head of Oncology at Advanced Accelerator Applications ("AAA"), she led the successful NDA resubmission strategy for Lutathera®, securing marketing authorization from both FDA and EMA following an initial Complete Response Letter. During her tenure, she served as the clinical lead for the Lu-PSMA program, overseeing IND submission, first-in-human Phase 1 trial design, and execution. With the successful completion of the above activities, AAA was acquired by Novartis.

Dr. Barton started her industrial career journey at Novartis Oncology after over 9 years as a medical oncologist in Sao Paulo, Brazil. She holds MD from Pontifical Catholic University of São Paulo and Federal University of São Paulo.

“We are thrilled to welcome Dr. Barton to Full-Life at this pivotal moment as we ramp up to bring multiple assets into global phase 1 trials," said Lanny Sun, Co-founder, Chairman and CEO of Full-Life Technologies. "Her unparalleled expertise in radiopharmaceutical clinical development, demonstrated through multiple successful regulatory approvals and clinical program executions, makes her the ideal leader for this critical phase of our growth. As our new Chief Medical Officer, Dr. Barton's strategic vision and innovative approach will be invaluable assets to our team.” 

About Full-Life Technologies

Full-Life Technologies ("Full-Life") is a clinical-stage, fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We aim to own the entire value chain for radiopharmaceutical research & development, production & commercialization to deliver clinical impact for patients. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and seasoned scientists with a proven history of success in the life sciences, alongside radioisotope research and clinical development.